Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdCh3NSmut1 and MVA-NSmut Vaccine for HCV Prevention
NCT01436357Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2012
- Primary completion
- May 2018
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AdCh3NSmut and MVA-NSmut in hepatitis C (HCV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 months, Number of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After First Vaccination and 3 more. Started Mar 2012; status: completed.
02
Drugs
AdCh3NSmutMVA-NSmut
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01436357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01436357.